Peter I Kalmar1, Rupert H Portugaller2, Peter Schedlbauer3, Dennis Bohlsen4, Hannes A Deutschmann5. 1. Medical University of Graz, Department of Radiology, Univ. Hospital Graz, Auenbruggerplatz 9, A-8036 Graz, Austria. Electronic address: peter.kalmar@medunigraz.at. 2. Medical University of Graz, Department of Radiology, Univ. Hospital Graz, Auenbruggerplatz 9, A-8036 Graz, Austria. Electronic address: rupert.portugaller@medunigraz.at. 3. Medical University of Graz, Department of Radiology, Univ. Hospital Graz, Auenbruggerplatz 9, A-8036 Graz, Austria. Electronic address: peter.schedlbauer@klinikum-graz.at. 4. Medical University of Graz, Department of Radiology, Univ. Hospital Graz, Auenbruggerplatz 9, A-8036 Graz, Austria. Electronic address: dennis.bohlsen@medunigraz.at. 5. Medical University of Graz, Department of Radiology, Univ. Hospital Graz, Auenbruggerplatz 9, A-8036 Graz, Austria. Electronic address: hannes.deutschmann@medunigraz.at.
Abstract
PURPOSE: Aim was to determine immediate results and mid-term outcome of the hemoparin-coated (HC) stainless-steel stent (camouflage coating) in the treatment of occlusive lesions of the iliac arteries. MATERIALS AND METHODS: Twenty-eight patients were prospectively treated with the use of a HC stent between January 2007 and March 2010. Clinical examination and color-doppler ultrasound were performed at 1, 3, 6 and 12 months, CT angiography (CTA) or MR angiography (MRA) at 12 months. Indication for treatment was a high-grade stenosis of the common iliac and/or external iliac artery. RESULTS: Successful placement was achieved in all patients. Significant decrease in translesional pressure gradient (>10 mm Hg) was measured in 27 patients (96%). In one patient, proximal dissection occurred without flow limitation. A minor complication (small access site hematoma) occurred in one patient (4%). Two patients (7%) were lost to follow-up. After 12 months, stent patency in CTA, MRA and ultrasound was 100%. 20 patients (77%) experienced an initial improvement of at least one clinical stage. In one patient (4%), mild intimal hyperplasia without significant stenosis was observed. In three patients (12%), proximal or distal stenosis occurred. A non-significant increase of mean ankle-brachial index (ABI) after treatment was measured (0.85 ± 0.27 vs. 0.75 ± 0.22, respectively; p=0.328). CONCLUSIONS: The use of HC stents in patients with iliac artery occlusive disease may lead to a lower rate of intimal hyperplasia and thus to increased patency rates even in heavily calcified vessels. However, large-scale prospective trials have to be performed to evaluate the long-term patency rates of the HC coated stents.
PURPOSE: Aim was to determine immediate results and mid-term outcome of the hemoparin-coated (HC) stainless-steel stent (camouflage coating) in the treatment of occlusive lesions of the iliac arteries. MATERIALS AND METHODS: Twenty-eight patients were prospectively treated with the use of a HC stent between January 2007 and March 2010. Clinical examination and color-doppler ultrasound were performed at 1, 3, 6 and 12 months, CT angiography (CTA) or MR angiography (MRA) at 12 months. Indication for treatment was a high-grade stenosis of the common iliac and/or external iliac artery. RESULTS: Successful placement was achieved in all patients. Significant decrease in translesional pressure gradient (>10 mm Hg) was measured in 27 patients (96%). In one patient, proximal dissection occurred without flow limitation. A minor complication (small access site hematoma) occurred in one patient (4%). Two patients (7%) were lost to follow-up. After 12 months, stent patency in CTA, MRA and ultrasound was 100%. 20 patients (77%) experienced an initial improvement of at least one clinical stage. In one patient (4%), mild intimal hyperplasia without significant stenosis was observed. In three patients (12%), proximal or distal stenosis occurred. A non-significant increase of mean ankle-brachial index (ABI) after treatment was measured (0.85 ± 0.27 vs. 0.75 ± 0.22, respectively; p=0.328). CONCLUSIONS: The use of HC stents in patients with iliac artery occlusive disease may lead to a lower rate of intimal hyperplasia and thus to increased patency rates even in heavily calcified vessels. However, large-scale prospective trials have to be performed to evaluate the long-term patency rates of the HC coated stents.